Introduction
Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous disease which is marked by uncontrolled clonal expansion of blast cells. 1 Although the new treatment strategies based on molecular biology of AML have been adopted in recent years, the prognosis of the disease remains poor. [2] [3] [4] It has become apparent that karyotype abnormalities have important value for AML diagnosis classification, prognostic evaluation, and guiding individual treatment. 5, 6 Cytogenetic aberrations together with several gene mutations including NPM1, CEBPA, TP53, TET2, DNMT3A, Recently, increasing number of research papers revealed that lncRNAs were relevant to many human diseases, especially to human cancers, and many studies began to explore the molecular mechanisms of lncRNA function in the pathogenesis of these disease or cancers. 11 With the deepening of the research, it is becoming increasingly apparent that most of the susceptibility to cancer is not caused by the variation of coding sequences of DNA but by the noncoding regulatory sequences, especially by lncRNAs. 10 lncRNA PANDAR, which is located at 6p21.2, plays a vital role in regulation of apoptosis by inhibiting the expression of proapoptotic genes through interaction with the transcription factor NF-YA. 12 To date, the abnormal expression of PANDAR has been reported in various solid cancers, such as hepatocellular carcinoma, gastric cancer, and breast cancer. 13 However, there are few reports about the expression of PANDAR in blood cancer. Therefore, we focused on exploring the PANDAR expression level and its connection with clinical implication in AML patients.
Materials and methods

Patients and treatment
A total of 119 de novo AML patients and 26 healthy donors were included in the present research, which was approved by the Ethics Committee and Institutional Review Board of the Affiliated People's Hospital of Jiangsu University. Bone marrow (BM) was collected from all the participants after they signed the informed consents. BM mononuclear cells (BMMNCs) were extracted from BM specimen using Lymphocyte Separation Medium (TBD Sciences, Tianjin, People's Republic of China). Treatment protocols for AML were described previously. 14 
Cytogenetics and mutation analysis
By conventional R-banding method, karyotype was analyzed at the time of initial diagnosis. Risk classification based on the karyotype findings has been done as previously reported. 15 Mutations in C-KIT, NPM1, DNMT3A, N/K-RAS, and U2AF1 were detected by high-resolution melting analysis, [16] [17] [18] [19] [20] whereas FLT3-ITD and CEBPA mutations were detected by direct DNA sequencing. 21, 22 Rna isolation and reverse transcription Total RNA was extracted by using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The specific procedure of reverse transcription was conducted as previously reported. 23 
Real-time quantitative PCR
The primers for PANDAR are as follows: forward: 5′-CTCCATCATGCCAA GTTCTGC-3′ and reverse: 5′-GAAGGCAGGCAAGACTCGAA-3′. PANDAR expression was detected by real-time quantitative PCR using AceQ qPCR SYBR Green Master Mix (Vazyme Biotech Co., Piscataway, NJ, USA). The reaction condition of real-time quantitative PCR was conducted as reported earlier. 24, 25 Relative PANDAR expression levels were calculated by 2 -ΔΔCT method.
statistical analysis
SPSS software version 20.0 (IBM Corporation, Armonk, NY, USA) was used to carry out the statistical analysis. Meanwhile, receiver operating characteristic (ROC) curve and area under the ROC were applied to assess the value of PANDAR expression. Besides, Pearson's chi-squared analysis was conducted to detect the difference of categorical variables between PANDAR high group and PANDAR low group. Through Kaplan-Meier method and Cox regression analysis, the effect of PANDAR expression on prognosis was analyzed. Logistic regression analysis was used to identify the independent risk factors of complete remission (CR). In all tests, P<0.05 was defined as statistically significant. 
Results
PanDaR expression in aMl
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PanDaR expression in aMl Figure 1 ). Besides this, significant upregulation of PANDAR was also found in non-M3-AML and cytogenetically normal AML subgroup of patients (Figure 1 ).
Distinguishing capacity of PanDaR expression
The ROC curve analysis was applied to evaluate whether PANDAR expression could be used as a biomarker for the diagnosis of AML. The results showed that area under the curve value was 0.800 (95% CI: 0.716-0.883), which suggested the PANDAR expression level might be a potential biomarker in discriminating AML from controls (P<0.001, Figure 2A ). In addition, when the cutoff value was 0.840, the sensitivity and specificity of diagnosis of AML were 65.5% and 80.8%. For non-M3-AML and CN-AML patients, significant differences also existed ( Figure 2B and C, respectively).
The connection between PanDaR expression level and clinical characteristics in aMl
By the set cutoff value based on the basis of ROC curve, the whole cohort of AML patients was divided into two groups. Table 1 ). We then analyzed the expression level of PANDAR in AML patients who achieved CR and those without CR, and showed it in scatter plots (P<0.001, Figure 3) . Additionally, clinical characteristics of patients with CR and non-CR were further compared. Significant differences were found in PANDAR expression, age, WBCs, BM blast, risk group, and karyotype finding (P<0.05, Table 2 ). Logistic regression analysis including the most predictive factors was further performed which revealed that PANDAR expression was an independent risk factor that affected CR in whole-cohort AML and non-M3 AML patients (P=0.010 and 0.005, respectively, Tables 3  and 4 ).
The relationship between PanDaR expression and prognosis in aMl patients
The survival analysis indicated that in the whole-cohort AML patients with high PANDAR expression had a shorter 
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PanDaR expression in aMl overall survival (OS) time than those who were in PANDAR low-expressed group (P<0.001, Figure 4A ). In non-M3 AML, patients with PANDAR high expression also had a shorter OS compared with those with PANDAR low expression (P=0.005, Figure 4B ). Regretfully, patients with PANDAR high expression did not presented a significant shorter OS than patients with PANDAR low expression among CN-AML (P=0.238, Figure 4C) 
Discussion
Lately, more and more researchers are devoted to exploring noncoding RNA and AML. 26 Many studies have proved Abbreviations: aMl, acute myeloid leukemia; CR, complete remission; hR, hazard ratio; OR, odds ratio; Os, overall survival; WBC, white blood cell. 
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PanDaR expression in aMl that lncRNAs indeed played an important regulatory role in human cancers, and it was closely related with the occurrence and the development of various tumors. 14, 27 Also, increasing number of research papers have shown that the abnormal expression of PANDAR was connected with the tumorigenesis of various solid tumors. [28] [29] [30] [31] [32] In the first report published by Hung et al, it was indicated that PANDAR inhibited the expression of proapoptotic genes by interacting with the transcription factor NF-YA. 12 
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Yang et al cancer initiation and progression, and it could serve as an oncogene in these cancers.
In the studies examining the expression level of PANDAR, many reports showed that PANDAR was associated with the prognosis of cancers. For instance, Li et al found that PAN-DAR was upregulated in thyroid cancer tissue and cell lines, and it could be a promising therapeutic target and important biomarker for thyroid cancer. 28 Similarly, an article reported that the expression level of PANDAR in hepatocellular carcinoma was crucially associated with the size of tumor nodule, vascular invasion, and TNM stage. 29 Moreover, overexpression of PANDAR was relevant to the poorer survival and shorter recurrence duration for the disease in hepatocellular carcinoma patients, and it could be recognized as a potential tumor biomarker and therapeutic target. 29 However, the effect of PANDAR expression on prognosis in blood malignancies remains poorly defined. Findings from our study demonstrated that high expression of PANDAR indicated a poor prognosis in AML patients. PANDAR expression level influenced CR rate, with the PANDAR high group having lower CR rate in comparison to the PANDAR low group. Logistic regression analysis showed that PANDAR expression was an independent prognostic factor for CR. More importantly, Kaplan-Meier survival analyses clearly showed that patients with higher expression of PANDAR had a shorter OS than those patients with lower expression. Univariate and multivariate Cox regression analyses revealed the increased PANDAR expression was an independent unfavorable risk factor in AML patients.
Our study was the first to report that PANDAR was upregulated in AML and was also the first to demonstrate the prognostic value of PANDAR in AML.
Conclusion
Expression of PANDAR was frequently upregulated in AML, and high expression of PANDAR as an independent unfavorable risk factor for CR and OS in whole-cohort and non-M3 AML patients. Therefore, our findings indicated that PANDAR was a potential biomarker for AML and it might effectively predict the outcome of AML patients.
